Newborn Metabolic Screening Market Size is Projected to Grow from US$ 295.7 Million in 2022 to US$ 757.9 Million by 2032, Exhibiting a CAGR of 8.9% | Persistence Market Research
22 janv. 2024 03h15 HE
|
Persistence Market Research
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Newborn Metabolic Screening Market Overview: The Newborn Metabolic Screening Market is a crucial component of newborn healthcare, aimed at detecting...
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey
08 janv. 2024 18h01 HE
|
Er-Kim
Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor across Central & Eastern Europe and Turkey
Accarent Health Announces Affiliation with Children’s Hospital Los Angeles to Provide Virtual Cardiology, Oncology and Musculoskeletal Second Opinion Services
02 janv. 2024 10h57 HE
|
Accarent Health
Baltimore, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- When your child has a health condition, you want the best possible care. Children’s Hospital Los Angeles (CHLA) provides exceptional family-centered...
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
20 déc. 2023 11h45 HE
|
Mithra Pharmaceuticals
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Behavioral Health Startup, ABC Medical, Offers Innovative Treatment Program
17 nov. 2023 14h59 HE
|
ABC Medical
Comprehensive treatment program for those experiencing mental illness
Pediatric Clinical Trials Market Size to Reach US$ 20.6 Billion by 2030, Driven by Increasing Prevalence of Chronic Diseases and Rising Demand for Pediatric-Specific Treatments
08 nov. 2023 06h01 HE
|
Rationalstat LLC
Wilmington, Delaware, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Global Pediatric Clinical Trials Market value is estimated at US$ 14.6 billion in 2023 and is expected to grow at a significant CAGR...
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
07 nov. 2023 08h50 HE
|
NeuroSigma, Inc.
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
26 oct. 2023 15h19 HE
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Accarent Health Offers Industry Leading Pediatric Network of Excellence
23 oct. 2023 12h48 HE
|
Accarent Health
Baltimore, MD, Oct. 23, 2023 (GLOBE NEWSWIRE) -- While most hospitals can treat children adequately for a broken bone or fever, relatively few children, compared with the total patient population,...
Mental Health Concerns for Children Approaching National Health Emergency in the U.S.
04 oct. 2023 14h38 HE
|
Omada Foundation for Children
LAGUNA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Mental health is the top pediatric safety concern in the United States for 2023, according to a new report from U.S. patient safety and...